Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.54 |
| ▸ | HPGD | P15428 | 3/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | RCE1 | Q9Y256 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30369928 | 1.00 | ALDH1A1 (0.54) | ALDH1A1CYP3A4HPGDHSD17B10TSHR | |
| SCHEMBL4077565 | 0.83 | ALDH1A1 (0.54) | ALDH1A1CYP3A4HPGDHSD17B10TSHR | |
| Hydrochloric Acid SCHEMBL7416083 | 0.81 | ALDH1A1 (0.52) | ALDH1A1CYP3A4HPGDHSD17B10TSHR | |
| SCHEMBL29498391 | 0.77 | PLAU (0.63) | ALDH1A1CYP3A4HPGDHSD17B10TSHR | |
| SCHEMBL30366550 | 0.77 | CYP1A2 (0.52) | ALDH1A1CYP1A2CYP2A6HPRT1IDO1 | |
| SCHEMBL29404930 | 0.77 | PLAU (0.63) | ALDH1A1CYP3A4HPGDHSD17B10TSHR | |
| SCHEMBL30366173 | 0.77 | CYP1A2 (0.52) | ALDH1A1CYP1A2CYP2A6HPRT1IDO1 | |
| SCHEMBL5748246 | 0.77 | CYP1A2 (0.52) | ALDH1A1CYP1A2CYP2A6HPRT1IDO1 | |
| SCHEMBL18530961 | 0.77 | CYP1A2 (0.52) | ALDH1A1HPGDHSD17B10TSHRCYP1A2 | |
| SCHEMBL5383334 | 0.77 | HPRT1 (0.54) | ALDH1A1CYP3A4HPGDHSD17B10TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250368641-A1 | QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORP (US) | 2025-12-04 | — | — | US | disclosed |
| US-12378243-B2 | Quinoline compounds as inhibitors of KRAS | INCYTE CORPORATION (US) | 2025-08-05 | — | — | US | disclosed |
| US-20250188073-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORP (US) | 2025-06-12 | — | — | US | disclosed |
| EP-4548918-A2 | TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS | Incyte Corporation (US) | 2025-05-07 | — | — | EP | disclosed |
| US-20240368152-A1 | QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORPORATION | 2024-11-07 | — | — | US | disclosed |
| EP-4415824-A1 | QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS | Incyte Corporation (US) | 2024-08-21 | — | — | EP | disclosed |
| CN-118525017-A | Quinoline compounds as KRAS inhibitors | 因赛特公司 | 2024-08-20 | — | — | CN | disclosed |
| US-12030883-B2 | Hetero-tricyclic compounds as inhibitors of KRAS | INCYTE CORPORATION (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030883-B2 | Hetero-tricyclic compounds as inhibitors of KRAS | INCYTE CORPORATION (US) | 2024-07-09 | — | — | US | disclosed |
| EP-4393915-A1 | ISOINDOLINONE COMPOUND AND USE THEREOF | Hangzhou Glubio Pharmaceutical Co. Ltd. (CN) | 2024-07-03 | — | — | EP | disclosed |
| EP-0985414-A2 | Method of treating glaucoma and ischemic retinopathy | Pfizer Products Inc. (US) | 2000-03-15 | — | — | EP | disclosed |
| EP-0931547-A1 | Piperazinyl-heterocyclic compounds in the treatment of psychiatric conditions | Pfizer Products Inc. (US) | 1999-07-28 | — | — | EP | disclosed |
| EP-0901789-A1 | Method of treating tourette's syndrome | Pfizer Products Inc. (US) | 1999-03-17 | — | — | EP | disclosed |
| EP-0279598-B1 | ARYLPIPERAZINYL-ALKYLENE-PHENYL-HETEROCYCLIC COMPOUNDS | PFIZER INC. (US) | 1993-09-15 | — | — | EP | disclosed |
| EP-0281309-B1 | PIPERAZINYL-HETEROCYCLIC COMPOUNDS | PFIZER INC. (US) | 1991-12-27 | — | — | EP | disclosed |
| US-4891375-A | Arylpiperazinyl-alkylene-phenyl-heterocyclic compounds | PFIZER INC. (US) | 1990-01-02 | — | — | US | disclosed |
| US-4883795-A | Piperazinyl-heterocyclic compounds | PFIZER INC. (US) | 1989-11-28 | — | — | US | disclosed |
| US-4831031-A | Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity | PFIZER INC. (US) | 1989-05-16 | — | — | US | disclosed |
| EP-0281309-A1 | Piperazinyl-heterocyclic compounds | PFIZER INC. (US) | 1988-09-07 | — | — | EP | disclosed |
| EP-0279598-A2 | Arylpiperazinyl-alkylene-phenyl-heterocyclic compounds | PFIZER INC. (US) | 1988-08-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12030883-B2 | Hetero-tricyclic compounds as inhibitors of KRAS | KRAS, NRAS, HRAS | ALDH1A1 3337/4885CYP3A4 3951/4885HPGD 1090/4885 |
| US-12378243-B2 | Quinoline compounds as inhibitors of KRAS | KRAS, NRAS, HRAS | ALDH1A1 1858/4885CYP3A4 3762/4885HPGD 647/4885 |
| US-20240368152-A1 | QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS | KRAS, NRAS, HRAS | ALDH1A1 1858/4885CYP3A4 3762/4885HPGD 647/4885 |
| US-20250188073-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS | KRAS, NRAS, HRAS | ALDH1A1 2204/4885CYP3A4 3923/4885HPGD 799/4885 |
| US-20250368641-A1 | QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS | KRAS, NRAS, HRAS | ALDH1A1 1858/4885CYP3A4 3762/4885HPGD 647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.